Pharmaceuticals
WuXi AppTec Named Constituent of the FTSE4Good Index Series for Third Consecutive Year
SHANGHAI, Aug. 5, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced its inclusion in the FTSE4Good Index Series for the third consecutive year....
2025-08-06 08:00
3401
Sanyou Bio Wins the "2025 Best Customer Satisfaction CRO Award"
SHANGHAI, Aug. 5, 2025 /PRNewswire/ -- The highly anticipated 7th China Bio Innovation Expo was recently held in grand fashion in Suzhou. At the awards ceremony onAugust 1, Sanyou Bio was honored with the "2025 Best Customer Satisfaction CRO Award" in recognition of its deep expertise and outstan...
2025-08-05 22:00
3852
Seegene Unveils CURECA™ and STAgora™ at ADLM 2025, Advancing the Next Stage of Diagnostics
* Dr. Jong-Yoon Chun, Chairman and CEO of Seegene, highlights progress toward fully automated and data-driven molecular testing * Introduction of CURECA™, the first fully unattended PCR automation system, and STAgora™, a real-time global data analytics platform * Technologies designed to sca...
2025-08-05 21:07
4873
Neopharma Technologies Appoints Exchange Listing to Manage U.S. IPO
NEW YORK, Aug. 5, 2025 /PRNewswire/ -- Neopharma Technologies Ltd (NTL), a leading MedTech company specializing in digital drug and impairment testing for workplace and public safety, has appointed Exchange Listing, LLC to manage its upcoming U.S. initial public offering (IPO), with plans to list...
2025-08-05 21:00
2912
iNtRON Bio, Demonstrated Toxin-Neutralizing Effect of IMPA™ Phage Engineering Technology in Colorectal Cancer Model and Completed the US Patent Application
• Successful validation of payloaded anti-colibactin toxin phage using IMPA™ technology • Demonstrated 'Dual-target Therapeutic Strategy' by bacterial eradication and toxin neutralization • Filed the US patent application for the candidate substance and preclinical studies including PoC unde...
2025-08-05 20:00
2398
Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Small Molecule Oral GLP-1R Agonist, ASC30, in Participants with Obesity or Overweight
- 13-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of two oral formulations of ASC30, a once-daily tablet, in 125 participants with obesity or overweight. - All 125 participants enrolled in just over one month; topline data expected in the fourth ...
2025-08-05 18:50
2359
Fapon Biopharma Announces the enrollment of the First Patient in the Phase I Clinical Trial of FP008, A First-in-Class Immunotherapy for Solid Tumors
DONGGUAN, China, Aug 5, 2025 /PRNewswire/ -- Fapon Biopharma, a biotech in developing therapeutic antibodies and fusion proteins, is delighted to announce the completion of the first patient enrollment inChina for its Phase I clinical trial of FP008 , a first-in-class immunotherapy for solid tum...
2025-08-05 16:30
2918
Sunshine Lake Pharma Co., Ltd. (06887.HK) Completes Listing, Market Capitalisation Expected to Rapidly Surpass RMB 50 Billion
GUANGZHOU, China, Aug. 5, 2025 /PRNewswire/ -- Sunshine Lake Pharma Co., Ltd. (06887.HK) announced that the company will officially list on the Hong Kong Stock Exchange onAugust 7th. Through this integration, the company has effectively combined its expertise in drug R&D with the mature nationwid...
2025-08-05 15:34
2373
Chugai Pharma Taiwan Honored at the AREA 2025 for its Social Empowerment and Green Innovation
BANGKOK, Aug. 4, 2025 /PRNewswire/ -- Chugai Pharma Taiwan (CPT), a subsidiary of Chugai Pharmaceutical Co., Ltd. inJapan, has been recognized in both the Social Empowerment and Green Leadership categories at the Asia Responsible Enterprise Awards (AREA) 2025. These recognitions highlight the com...
2025-08-05 13:02
3110
WuXi XDC Achieves GMP Release of Newly Launched DP3 Facility at Wuxi Site, Scaling Further Drug Product Manufacturing Capacity
WUXI, China, Aug. 4, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announced that the Drug Product 3 ("DP3") facility at the Wuxi site has c...
2025-08-05 10:13
3160
Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032
SAN FRANCISCO and SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2025-08-05 08:00
2638
LA ROCHE-POSAY AND GLOBAL SKIN HEALTH EXPERTS UNITE TO WARN ABOUT LONG TERM CONSEQUENCES OF DANGEROUS 'BURN LINES' SOCIAL MEDIA TREND
PARIS, Aug. 5, 2025 /PRNewswire/ -- A viral TikTok challenge known as "Burn Lines" or "Sunburn Tattoos" is gaining alarming traction among teenagers and young adults worldwide. The trend, which involves placing tape or stencils on the skin to intentionally burn patterned tan lines, has sparked wi...
2025-08-05 05:15
2445
Raytone Biotech Announces First Patient Dosed in Clinical Trial of RTP-008 for Dry Eye Disease
BEIJING, Aug. 3, 2025 /PRNewswire/ -- Raytone Biotech, a clinical-stage biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient dosing in its clinical trial of RTP-008 during Q2 2025. RTP-008 is a bioabsorbable tacrolimus lacr...
2025-08-04 14:29
1839
Raytone Biotech Announces First Patient Dosed in Clinical Trial of RTP-008 for Dry Eye Disease
BEIJING, Aug. 4, 2025 /PRNewswire/ -- Raytone Biotech, a biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient dosing in its clinical trial of RTP-008 during Q2 2025. RTP-008 is a bioabsorbable tacrolimus lacrimal canalic...
2025-08-04 14:05
2241
Akeso Announces Approval to Initiate Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma
HONG KONG, Aug. 4, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225) has been approved to initiate by bothChina's National Medical Products Administration (NMPA) and the ...
2025-08-04 13:56
2504
Alphamab Oncology Announces IND Application for Innovative PD-L1/αvβ6 Bispecific ADC JSKN022 was Officially Accepted by CDE
SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and integrin αvβ6, has been officially acce...
2025-08-04 09:28
3363
Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics
Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2
Clinical Trials and First-in-Human Studies
CAMBRIDGE, Mass. and BIRMINGHAM, Ala. and RAICHUR, India, Aug. 4, 2025
/PRNewswire/ --Alveolus Bio
2025-08-04 08:00
3679
First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma's Investigational Antidepressant Targeting NET/DAT/GABAAR
SHANGHAI, Aug. 3, 2025 /PRNewswire/ -- Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial inChina for its LY03021, which was filed throughChina's Class 1 pathway for innovative drugs. LY03021 is an inhibitor of the norepinephrine transporter (NE...
2025-08-03 18:23
4792
Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA
SHANGHAI, Aug. 1, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its proprietary CDH17-targeting antibody-drug conjugate (ADC), 7MW4911, has received Investigational New Drug (IND) application acceptance fromChina's Na...
2025-08-01 22:00
4325
Everest Medicines Expands Strategic Investment in I-MAB
- Everest will invest US$30.9 million (equivalent to approximately HK$242.6 million) in cash in I-Mab. Inclusive of I-MAB shares already held by Everest, the pro forma ownership will be 16.1%. - I-Mab's Claudin 18.2 x 4-1BB bispecific antibody, givastomig, demonstrated an impressive overall resp...
2025-08-01 21:02
4437
Week's Top Stories
Most Reposted
OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1141 media titles]
2026-11-05 06:52Royal Bank of Canada announces agreement to acquire Yarra Capital Management
[Picked up by 1141 media titles]
2026-11-09 21:00Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
[Picked up by 1121 media titles]
2026-11-06 22:06
Cision Report Reveals the Consumer Trends Hidden Between Search, Social, and AI
[Picked up by 1105 media titles]
2026-11-09 23:00
Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1083 media titles]
2026-11-03 22:00Most Read
Home Companion Robot Mobo to Debut Globally and Open Pre-orders as AiMOGA Showcases Its Robot Family at the 2026 OMODA & JAECOO International User Summit
2026-11-07 13:49
25907
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
22325
